menu

Treatment HBV and HDV infection

Myrcludex B

MYR Pharma is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection.

Treatment HBV and HDV infection

Myrcludex B

MYR GmbH is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection.

Treatment HBV and HDV infection

Myrcludex B

MYR GmbH is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection.

Welcome to Myr Pharma website

features

MYR Pharma is focused on the development of Myrcludex B, a first-in-class drug for the treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infections. Myrcludex B targets the essential hepatocyte protein NTCP and prevents the viruses from spreading in the liver. As the first drug - entry inhibitor of HBV and HDV, Myrcludex B has a landscape-changing potential in both indications.

As an inhibitor of bile acid transporter NTCP, Myrcludex B also opens up new possibilities for the treatment of a variety of inflammatory and metabolic diseases.

More information

If you want to collaborate with Myr Pharma please contact

In addition to the license agreement, MYR has a collaboration and research agreement with the University Hospital Heidelberg!

Contact us!

our investors and partners